Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission
Loading...
Files
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier Ltd
Abstract
Description
Keywords
Anemia, sickle cell, Global health, Hematology, Humans, Aciclovir, Amlodipine, Bch bb694, Betibeglogene autotemcel, Cefepime, Ceftazidime, Cotrimoxazole, Filgrastim, Fluconazole, Gene therapy agent, Hemoglobin gamma chain, Hydralazine, Hydroxyurea, Labetalol, Levetiracetam, Magnesium sulfate, Unclassified drug, Vancomycin, Voxelotor, Africa, Allogeneic hematopoietic stem cell transplantation, Blood cell count, Blood transfusion, Bone necrosis, Cell therapy, Cerebrovascular disease, Chronic pain, Clinical evaluation, Cognitive defect, Comorbidity, Coronavirus disease 2019, Data analysis, Data base, Data quality, Data quantity, Demographics, Disease severity, Disease surveillance, Economic cost, Education program, Environmental factor, Environmental risk, Erythrocytapheresis, Evidence based practice, Gene addition therapy, Gene editing, Gene therapy, Genetic counseling, Genetic risk factor, Genetic screening, Genetic trait, Geographic mapping, Global disease burden, Gynecologist, Health care access, Health care cost, Health care disparity, Health care financing, Health care personnel, Health care system, High income country, Human, Implementation science, In vivo gene transfer, Infection, Kidney disease, Lancet hematology commission, Leg ulcer, Life expectancy, Medical assessment, Medical service, Medical student, Middle income country, Mortality, Network analysis, Newborn morbidity, Newborn screening, Nursing care, Obstetrics, Outcome assessment, Pandemic, Phase 1 clinical trial (topic), Phase 2 clinical trial (topic), Point of care testing, Practice guideline, Prevalence, Priapism, Prospective study, Psychotherapy, Public health insurance, Pulmonary hypertension, Quality control, Review, Risk factor, Sickle cell anemia, Sickle cell crisis, Sociodemographics, Training, Vitreoretinal surgery